AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the U.S. by 2030, the latest big investment by a pharmaceutical company reacting to President Donald Trump's tariff policy.
Breakdown
- AstraZeneca will invest $50 billion in the US by 2030, including a new factory in Virginia.
- The investment comes as the US considers tariffs on imported pharmaceuticals and urges more domestic production. 16s
- AstraZeneca's CEO said global drug prices should equalize, with higher prices outside the US to support R&D. 32s
- The US government has indicated tariffs may be imposed soon, with companies given up to 18 months to adjust. 47s
- AstraZeneca's move follows similar investments by other major pharmaceutical firms and is expected to create tens of thousands of jobs. 1m 14s
See The Full Story

Global Tariffs
Donald Trump has signed an order to impose tariffs imports into the U.S. from countries including China, Mexico and Canada.